Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor-positive breast cancer.
|
31690650 |
2020 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
|
30389903 |
2019 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
|
30914635 |
2019 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation.
|
31439820 |
2019 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib is a Cdk4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer.
|
30772267 |
2019 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer.
|
29669860 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers.
|
29497091 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer.
|
30206110 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We reviewed clinical trials on antiestrogen agents combined with the CDK4/6 inhibitor (Palbociclib, Ribociclib, or Abemaciclib) in ER-positive breast cancer.
|
29236235 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The emergence of CDK4/6 inhibitors has changed the treatment algorithm for advanced/metastatic estrogen receptor-positive breast cancer.
|
29784737 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abemaciclib, a CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS mutant lung cancer.
|
29059158 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
|
29483206 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors have already been FDA approved for the treatment of estrogen receptor (ER)-positive breast cancer and are being tested in numerous other cancer types.
|
29934327 |
2018 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two major clinical challenges remain: (i) adverse events leading to therapy discontinuation and (ii) lack of reliable biomarkers.
|
28653662 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A recent phase III trial has shown that fulvestrant combined with a CDK 4/6 inhibitor doubles PFS in aromatase inhibitor-pretreated postmenopausal ER+ breast cancer.
|
28529550 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extending the use of CDK4/6 inhibitors beyond ER-positive breast cancer is challenging, and will likely require biomarkers that are predictive of a response.
|
28395543 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the p16INK4a/cyclin D/CDK4/6/RB pathway is an effective therapeutic strategy for the treatment of estrogen receptor positive (ER+) breast cancer.
|
28418845 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treating ER+ Breast Cancer with CDK4/6 Inhibitors.
|
28626036 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
|
28249908 |
2017 |
Oestrogen receptor positive breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future trials evaluating further combination strategies with CDK 4/6 backbone and translational studies refining predictive biomarkers are needed to help personalize the optimal treatment regimen for individual patients with ER+ breast cancer.
|
26896604 |
2016 |